Acute Infective Endocarditis

Jay R. McDonald, MD\textsuperscript{a,b,*}

Despite advances in medical and surgical therapy, infective endocarditis (IE) remains a highly morbid and deadly infection. Endocarditis is an inflammation of the endocardium, the inner lining of the heart and heart valves. While such inflammation can be caused by a variety of disease states, infectious agents cause most cases of endocarditis.

In his Gulstonian lectures of 1885, Sir William Osler drew a distinction between “simple” and “malignant” forms of endocarditis.\textsuperscript{1} The “simple” form described by Osler correlates to what has become known as subacute bacterial endocarditis. Subacute IE typically presents with subtle constitutional symptoms and is frequently not diagnosed until it has been present for months. The “malignant” form described by Osler, characterized by an acute onset and fulminant course, correlates to what is now known as acute IE. The focus of this review is acute IE, though many studies of diagnosis and treatment do not differentiate between acute and subacute disease, and indeed many principles of diagnosis and management of IE for acute and subacute disease are identical.

PATHOGENESIS

Vegetation formation is a multistep process. The first step is endocardial injury, which may occur by many mechanisms. The most common mechanism is injury by turbulent blood flow from an acquired or congenital intracardiac abnormality. The most common site of such injury, and thus the most common site of vegetation formation, is on the line of closure of a valve surface, typically on the atrial surface of atrioventricular valves or on the ventricular surface of semilunar valves.\textsuperscript{2} Alternatively, an
intravascular catheter or other device may directly abrade the endocardium. In injection drug users, direct injection of contaminating debris may damage the tricuspid valve surface.

The endothelial damage triggers sterile thrombus formation, which occurs by deposition of fibrin and platelets. Though mechanical endocardial damage usually precedes sterile thrombus formation, a sterile thrombus can be induced without direct trauma. Physiologic stresses, such as hypersensitivity states, hormonal changes, and high altitude, can also induce sterile endocardial thrombosis. Clinical states associated with sterile thrombus formation in humans include malignancy, rheumatic diseases, and uremia.

Once a sterile thrombus is present, transient bacteremia can seed the thrombus. Bacteria are introduced into the bloodstream when a body surface heavily colonized by bacteria (oral cavity, gut lumen, genitourinary mucosa) is traumatized. Routine daily activities, such as chewing food and brushing teeth, lead to frequent low-level, transient bacteremias in healthy adults. Blood-borne bacteria may adhere to the damaged endocardial surface. Bacteria have different adhesive capacities based on bacterial surface characteristics and virulence factors, called adhesins. For example, the adhesive properties of viridans streptococci are related to the amount of dextran present in the streptococcal cell wall, as well as specific surface proteins, such as FimA.

Once bacteria have attached to the endocardium, the vegetation “matures” through additional deposition of fibrin and bacterial proliferation. Histologically, the vegetation consists primarily of fibrin, platelets, and bacteria; the absence of vasculature makes penetration by phagocytic cells rare. The majority of bacteria in mature vegetation are found below the surface of the vegetation, protected from phagocytes and high concentrations of antibiotics.

**EPIDEMIOLOGY**

*Demographics and Risk Factors*

The incidence of IE is between 2 and 10 episodes per 100,000 person-years in most population-based studies, and as high as 20 episodes per 100,000 person-years in the elderly. There are approximately 15,000 new cases of IE diagnosed each year in the United States, and it accounts for about 1 in 1000 admissions to the hospital.

Most studies demonstrate that the rate of IE has been stable over time, though changes in diagnostic tools and criteria make temporal comparisons difficult. Despite a relatively stable rate, the nature of IE has changed dramatically over the past several decades. IE is more commonly associated with invasive medical procedures and old age, and less associated with rheumatic heart disease and poor dentition. These epidemiologic trends support the observation that acute IE is increasing in frequency relative to subacute and chronic IE: In the pre-antibiotic era, approximately 20% of IE was acute, while more recent studies show that about 33% of IE is acute.

IE is more common in men than women, and is more common with increasing age. The mean age of IE patients has increased over time, from under 30 years in the pre-antibiotic era to nearly 60 years in the 1990s. In the elderly, IE is more often associated with intracardiac prosthetic devices and bacteria from the gastrointestinal tract. In a large observational cohort study, IE most commonly involved the mitral valve only (approximately 40% of patients), followed by the aortic valve only (36% of patients), followed by multivalvular disease. Right-sided valves are rarely affected except among injection drug users. The pulmonic valve is least likely to be involved in IE.
Structural heart disease is a risk factor for IE because it results in turbulent blood flow. About 75% of patients who develop IE have underlying structural heart disease. In the past, rheumatic heart disease with mitral stenosis was the most common valvular defect in patients with IE. Recently, the most common predisposing lesions have been mitral regurgitation, aortic valve disease (stenosis and regurgitation), and congenital heart disease. Mitral valve prolapse is a risk factor for IE, primarily when regurgitation is present.

The presence of a prosthetic cardiac valve is a strong risk factor for IE. The risk is highest in the first year after valve implantation. Mechanical valves are associated with higher risk than bioprosthetic valves in the first years after surgery, but that relationship reverses in later years after surgery. Implanted valve rings are associated with lower risk of IE than prosthetic valves.

In addition to structural heart disease and prosthetic valves, established risk factors for IE include prior episodes of IE, invasive medical procedures, and injection drug use. Some studies have demonstrated that diabetes mellitus and kidney disease may be risk factors as well.

Nosocomial IE is increasing in frequency and importance. Between 14% and 31% of all IE is nosocomial in recent case series. In a longitudinal single-center study in Spain, the proportion of IE acquired in the hospital increased almost 10-fold in a 15-year period. Compared with community-acquired IE, nosocomial IE was associated with threefold higher mortality, and was most commonly caused by *Staphylococcus aureus*, coagulase-negative staphylococci, and enterococci.

**Infective Endocarditis in Critical Care**

Because IE often occurs in patients with multiple comorbid illnesses and those who have undergone recent invasive procedures, it is commonly diagnosed and treated in the intensive care unit (ICU).

From 1993 to 2000, IE was diagnosed in 3% of ICU patients in two medical ICUs in France. Among 228 cases of IE in this study, 64% of cases were native valve endocarditis (NVE), of which 21% were nosocomial. *S. aureus* was the causative agent in half of all IE cases. Complications were frequent: Neurologic events complicated 40% of cases, congestive heart failure (CHF) 29%, and septic shock 26%. In-hospital mortality was 45%. Septic shock, neurologic complications, and immunocompromise predicted in-hospital mortality.

In another study, which took place between 1994 and 1999, IE was identified in 0.8% of all ICU patients in four medical ICUs in Vienna, Austria. Just over half of the 33 patients came to the ICU with the diagnosis of IE, while 45% were first diagnosed in the ICU. The majority (79%) had NVE, and *S. aureus* was the most common pathogen, causing 36% of IE. Severity of illness was high, with 79% of patients receiving mechanical ventilation, 73% receiving vasopressors, and 54% dying during their hospital stay. Acute renal failure occurred in 39% of patients, and was the only independent predictor of mortality.

Nosocomial IE in the ICU can usually be attributed to a hospital-acquired infection at another primary site. Of 31 nosocomial cases of IE described by Mourvillier and colleagues, 21 were related to intravenous catheter infection and three to surgical site infection. In another study, among 22 nosocomial IE cases in an ICU, 11 were related to an intravascular device and eight to a surgical site infection. Fifteen of these 22 patients had no predisposing cardiac lesion. *S. aureus* was the causative pathogen in 68% of patients, and 68% of the patients died.

Wolff and colleagues described 122 cases of prosthetic valve endocarditis (PVE) in a French ICU from 1978 to 1992. *S. aureus* accounted for 61% of disease occurring
in the first 2 months after valve implantation, and streptococci and \textit{S aureus} were the most common causes of late disease. Heart failure was seen in half of cases, and mortality was 34% at 4 months. Predictors of mortality among \textit{S aureus} cases were septic shock, heart failure, mediastinitis, and elevated prothrombin time.\textsuperscript{32}

\section*{APPRAOCH TO THE PATIENT}
\subsection*{Diagnosis}
\ \textbf{Diagnostic criteria}

The Duke criteria incorporate information from echocardiography, history and physical examination, microbiology, and pathology to diagnose IE (Box 1). They were originally proposed in 1994,\textsuperscript{33} and were subsequently shown to be superior to previous diagnostic criteria.\textsuperscript{34,35} The criteria were modified in 2000 to revise the definition of “possible IE,” add criteria for microbiologic diagnosis of Q fever IE, eliminate echocardiographic minor criteria, and include recommendations for choosing between transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE).\textsuperscript{36}

\subsection*{History and physical examination}

The clinical presentation of subacute IE is variable, but the presentation of acute IE is more straightforward. Unlike patients with subacute IE who typically report longstanding constitutional symptoms, patients with acute IE typically describe the abrupt onset of fever and rigors, and may present with symptoms of embolism. The history should include specific inquiry about known risk factors for IE, including invasive procedures, injection drug use, structural heart disease, and prior endocarditis. Symptoms referable to other organ systems may indicate a primary source of bacteremia. Complications of IE may be apparent from the history, including heart failure, conduction disturbances, or embolism.

The physical examination must be comprehensive, with special attention to examination of the heart, dentition, all sites of invasive devices and recent procedures, and potential destinations of embolism. Heart murmur is present in 85% of patients with IE, but a changing murmur is only apparent in 5% to 10% of cases. About half of patients with IE have evidence of embolic phenomena on physical examination.\textsuperscript{2,11} When clinical suspicion is present, a lack of clinical findings does not rule out the diagnosis of IE.

\subsection*{Laboratory tests}

At least three blood cultures should be drawn when IE is suspected, with the first and last drawn at least 1 hour apart. If fastidious organisms are suspected, the microbiology laboratory should be informed that IE is on the differential diagnosis. Electrocardiogram, chest radiograph, urinalysis, and rheumatoid factor may assist in making the diagnosis or identifying complications of IE.

\subsection*{Echocardiography}

Diagnosis of IE is made in part by echocardiographic findings. The presence of an oscillating intracardiac mass, either on a valve, in the path of a regurgitant jet, or on implanted material, is the classic finding, though abscess or new partial dehiscence of a prosthetic valve also meets diagnostic criteria.\textsuperscript{36} Other findings associated with IE include aneurysm, fistula, and leaflet perforation.\textsuperscript{37}

The use of echocardiography to rule out IE should be based on the clinician’s pretest probability of disease. Pretest probability, in turn, is based on the presence of clinical and microbiologic features unique to each patient, including the likelihood of alternative diagnoses. Studies have proposed algorithms for use of echocardiography to diagnose IE.\textsuperscript{38,39} While these studies cannot substitute for the judgment of an experienced clinician, they highlight some of the features that affect pretest
TTE and TEE both have a role in the diagnosis and evaluation of IE. TTE has low sensitivity compared with TEE (46% versus 93%), though both are highly specific (95% versus 96%).

TTE is a reasonable first test in patients with low pretest probability of IE despite its sensitivity of less than 50%. In some patients who undergo TTE and are found to have IE, subsequent TEE may be advisable to evaluate perivalvular extension of disease, vegetation size, and other factors that may inform surgical decision-making. In patients with higher pretest probability for disease, or in whom TTE is rendered less sensitive by obesity, lung hyperinflation, or valve prosthesis, TEE is the initial echocardiographic modality of choice in IE. Several studies have demonstrated that TTE alone will miss a significant number of cases of IE in patients

---

**Box 1**

**Modified Duke criteria for diagnosis of infective endocarditis**

**Major criteria**

Microbiologic evidence of IE

- Typical organisms cultured from two separate blood cultures:
  - Viridans streptococci, *S aureus*, HACEK (*Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, or Kingella*) organism, or *Streptococcus bovis*; or community-acquired enterococcus in the absence of an alternative primary site of infection

- Persistently positive blood cultures with other organism
  - At least two positives drawn more than 12 hours apart; or all of three or majority of four, with first and last drawn more than 1 hour apart

- One culture (or phase 1 IgG > 1:800) for *Coxiella burnetii*

Evidence of endocardial involvement

- Echocardiogram showing oscillating intracardiac mass without alternative explanation, or abscess, or new partial dehiscence of prosthetic valve, or new valvular regurgitation

**Minor criteria**

Predisposition to infective endocarditis

- Previous IE, injection drug use, prosthetic heart valve, or cardiac lesion causing turbulent blood flow

Fever over 38°C

Vascular phenomenon

- Arterial embolism, pulmonary infarct, mycotic aneurysm, intracranial or conjunctival hemorrhage, or Janeway lesions

Immunologic phenomenon

- Glomerulonephritis, Osler nodes, Roth spots, or positive rheumatoid factor

Microbiologic finding not meeting major criteria

- Definite endocarditis requires two major criteria, or one major and three minor criteria, or five minor criteria. Possible endocarditis requires one major and one minor criterion, or three minor criteria.

with medium to high pretest probability of disease, including those meeting Duke criteria for “possible” IE, and patients with \textit{S aureus} bacteremia.\textsuperscript{41,42}

\textbf{Alternative imaging modalities}

Cardiac CT and MRI have been reported to diagnose complications of IE, including aortic root abscesses and arteriovenous fistulae.\textsuperscript{37} Current limitations to these modalities include difficulties in evaluating valve motion, spatial resolution, and time required to acquire images.\textsuperscript{37} A recent study of cardiac multislice CT showed that its test characteristics were similar to those for TEE for the diagnosis of IE in 37 patients, 29 of whom underwent cardiac surgery, though all four leaflet perforations were missed with CT.\textsuperscript{43} While CT and MRI may be useful as an adjunct to echocardiography in selected cases at centers with expertise in these techniques, they are not part of the current standard of care in the routine diagnosis of IE. The technology involved in cardiac CT and MRI is evolving rapidly, and at some point in the future cardiac CT and MRI may be useful in IE diagnosis.

\textbf{Antibiotic Therapy: General Principles}

All patients with IE should receive antibiotic therapy, and more than half of cases are managed with antibiotic therapy alone.\textsuperscript{40} Some organism-specific recommendations for treatment are discussed below in the section on specific organisms. A recent scientific statement by the American Heart Association provides an excellent summary of evidence and antibiotic recommendations, and should be consulted for IE cases that are beyond the scope of this review.\textsuperscript{40}

Though treatment must be individualized, some general principles of antibiotic therapy apply to all patients. Because the vegetation structure sequesters bacteria from the bloodstream, long durations of therapy are necessary. Parenteral antibiotics are preferred over oral regimens because of the need for sustained and reliable blood levels of antibiotic. Blood cultures should be drawn every 24 to 48 hours after initiation of antibiotics, until they are negative. Duration of treatment should be counted from the time of the first negative blood cultures. If vancomycin or an aminoglycoside is used, drug levels should be monitored to ensure adequate dosing and to prevent toxicity.\textsuperscript{11,40}

Aminoglycosides are often used in combination with a cell wall–active agent (\(\beta\)-lactam or vancomycin) for synergy in the treatment of IE caused by staphylococci, streptococci, and enterococci. Cell wall–active agents increase aminoglycoside entry into bacteria, and therefore synergy requires dosing in close temporal proximity to one another. The use of combination therapy is supported by in vitro and animal studies, but clinical data in humans are scarce.\textsuperscript{44} A recent meta-analysis of clinical trials of combination therapy included 261 patients with IE due to \textit{S aureus} or viridans streptococci in five separate studies. There was no benefit of combination therapy in terms of mortality or treatment success.\textsuperscript{45} However, in a single study, combination therapy for \textit{S aureus} IE did reduce the duration of bacteremia, though it did not improve clinical outcomes.\textsuperscript{46} Because of the small size of these studies, it is possible that a meaningful clinical benefit does exist, but studies have not been adequately powered to detect it.

\textbf{Surgical Therapy}

Decisions regarding surgical therapy for patients with IE are multifactorial and complex, and the need for surgery should be individualized to each patient. For these reasons, early input from an experienced cardiothoracic surgeon can be invaluable in managing a patient with IE. Among all patients with IE, 40% to 45% eventually undergo surgery, and rates of surgery are similar for NVE and PVE. Predictors of surgery include younger
age, CHF, abscess, and coagulase-negative staphylococcal IE. The majority of surgery for IE is performed for hemodynamic indications, such as CHF.

Because there have been no randomized controlled trials of surgical plus medical therapy versus medical therapy alone in the treatment of IE, current guidelines for surgical treatment of IE are based primarily on observational data, which are prone to biases, such as confounding by indication and survival treatment selection bias. Because of these biases, careful adjustment for factors associated with risk of death and likelihood of receiving surgery is necessary.

Several recent studies have attempted to account for these factors, and results have been conflicting regarding the benefit of surgery. In a study reporting a 10-year experience at seven United States hospitals, 230 of 513 adults with NVE underwent cardiac surgery. After propensity analyses to account for differences in treatment assignment and prognostic factors, surgery was associated with reduced mortality (15% versus 28%, \( P = .01 \)), especially in patients with moderate to severe heart failure (14% versus 51%, \( P = .001 \)). In contrast, a study that matched 27 surgical and 27 nonsurgical ICU patients with IE by propensity score found no benefit of surgery (odds ratio 0.96). A study of NVE from the International Collaboration on Endocarditis Merged Database, which included patients from seven centers in five countries, showed a survival benefit from surgery only in patients in the highest quintile of surgical likelihood (11.2% in the surgery group versus 38.0% in the no-surgery group, \( P < .001 \)). A study of PVE from the same study group found a statistically nonsignificant benefit of surgery (22.1% in the surgery group versus 32.4% in the no-surgery group, \( P = .18 \)) in patients with PVE matched on propensity score. Finally, in an analysis of an 18-year experience with left-sided IE at a single center in the United States, after matching by propensity score, decade of diagnosis, and follow-up time, surgery was not significantly associated with mortality (adjusted hazard ratio (HR) 1.3, 95% CI 0.5–3.1). Thus, the benefit of surgery is unclear, and is likely restricted to specific subgroups of patients.

There are several subgroups of patients in which early surgery should be strongly considered. Patients with CHF or severe valvular dysfunction likely to precipitate acute CHF should be considered for surgery, particularly when the aortic valve is involved. Patients with intracardiac abscess should be strongly considered for surgery, in light of decreased penetration of antibiotics to the site of infection, and the possibility of the abscess causing heart block acute valvular dysfunction. Patients with IE caused by organisms known to be refractory to medical management, including Pseudomonas, Candida, and multidrug-resistant organisms, may benefit from surgical management, as well as those at highest risk for embolism.

Patients with PVE should be carefully considered for surgery, though low-risk patients with PVE may be adequately managed with medical therapy alone. Characteristics that suggest lower risk include absence of heart failure, abscess, or valve dehiscence, and those whose IE is caused by less virulent organisms, such as viridans streptococci.

**Right-Sided Infective Endocarditis**

Right-sided IE, which accounts for about 10% of cases of IE, occurs most commonly in injection drug users, and has different clinical characteristics and outcomes compared with left-sided IE. Patients with right-sided IE are typically younger and have fewer comorbid medical conditions and less underlying valve disease than patients with left-sided IE. S aureus is responsible for about 70% of right-sided IE. Patients with right-sided IE often present with signs and
symptoms of septic pulmonary emboli, including pleuritic chest pain, dyspnea, and hemoptysis. More than half present with chest radiograph consistent with septic pulmonary emboli.\textsuperscript{64} The mortality rate among patients with right-sided IE is typically less than 10\%.\textsuperscript{14,61,62}

In a study of 1529 episodes of IE in injection drug users in Spain, 79\% had right-sided IE, 16\% had left-sided IE, and 5\% had both.\textsuperscript{61} Only 1\% of the right-sided IE was of the pulmonic valve. It has not been definitively established why the tricuspid valve is so frequently involved in IE in injection drug users. While it may be related to valve damage caused by bombardment of the tricuspid valve by impurities in injected material, this damage has not always been apparent in autopsy studies of injection drug users. Other theories include drug-induced microthrombi on the valve, drug-induced pulmonary hypertension, and increased right-sided expression of molecules that bind bacteria.\textsuperscript{61,63}

Carefully selected cases of tricuspid valve IE may be managed with short courses of parenteral antibiotics, or with oral regimens.\textsuperscript{40,61,62,65,66} Patients with factors associated with poor prognosis, including concurrent left-sided IE, metastatic infection, heart failure, large vegetation, or immune compromise should not be considered for shorter course therapy or oral regimens.\textsuperscript{40}

**Prosthetic Valve Endocarditis**

The risk of PVE is 1\% to 5\% in the first year after implantation, and decreases to about 1\% per year thereafter.\textsuperscript{67,68} The risk of PVE is similar overall among mechanical and bioprosthetic valves, though early IE risk may be higher and late IE risk lower among mechanical valves compared with bioprosthetic valves.\textsuperscript{68–70} PVE risk is comparable among valves in the aortic and mitral positions.\textsuperscript{68–70} PVE occurring in the first 12 months after surgery is most often caused by coagulase-negative staphylococci or \textit{S aureus},\textsuperscript{69} while late-onset PVE has similar microbiology to NVE.\textsuperscript{70,71} Mortality in PVE is predicted by heart failure, \textit{S aureus}, and the presence of intracardiac abscess or fistula.\textsuperscript{32,60,72,73}

Surgical therapy for PVE is frequently indicated, as discussed above, and is performed in about half of all cases of PVE.\textsuperscript{73} Recommendations for medical therapy in the treatment of PVE are generally similar to those for treatment of NVE, though they differ substantially for staphylococcal PVE. For PVE caused by oxacillin-susceptible strains of staphylococci, duration of nafcillin or oxacillin should be at least 6 weeks, rifampin should be added for the same duration, and low-dose gentamicin should be given for 2 weeks.\textsuperscript{40}

**Cardiovascular Device–Related Infective Endocarditis**

Use of intracardiac pacemakers and implantable cardioverter-defibrillators (ICDs) has been steadily increasing, but infection of these devices has been increasing even more rapidly.\textsuperscript{74} Most infections of pacemakers and ICDs occur only at the pocket, but 10\% of pacemaker-associated infections include IE.\textsuperscript{75} Pacemaker/ICD IE is best diagnosed with TEE, as TTE has sensitivity of less than 30\% for lead vegetations.\textsuperscript{76,77} However, it may be impossible to definitively distinguish a sterile thrombus from an infected thrombus on a lead.\textsuperscript{2} An intracardiac oscillating mass on a pacemaker/ICD lead qualifies as a major criterion in the Duke criteria for IE diagnosis.\textsuperscript{36}

There have been no randomized studies of device removal plus antibiotics versus antibiotics alone in the treatment of pacemaker/ICD IE, but optimal management includes removal of the device, at a minimum until bacteremia clears, but longer if possible. One retrospective study of any pacemaker/ICD infection showed a relapse rate of less than 1\% among 117 patients who underwent device removal, and 50\%
among 6 patients in whom the device was retained.\textsuperscript{77} If a pacemaker/ICD must be replaced before completion of therapy, it may be advisable to treat as PVE.

**SPECIFIC ORGANISMS**

For IE caused by organisms not addressed below or in Tables 1 and 2, the American Heart Association’s Scientific Statement on Infective Endocarditis should be consulted for treatment recommendations.\textsuperscript{40}

**Staphylococcus aureus**

*S aureus* is the leading cause of acute IE. The incidence of *S aureus* IE has been steadily increasing in recent decades, becoming the predominant organism in IE in most reports.\textsuperscript{40,78,79} Increasing use of intravenous catheters and implanted prosthetic devices has led to higher rates of health care–associated staphylococcal bacteremia, placing more patients at risk for IE.\textsuperscript{79}

*S aureus* IE tends to involve the mitral valve more often than the aortic, and is the most common cause of IE among injection drug users.\textsuperscript{18} IE caused by community-associated strains of methicillin-resistant *S aureus*, compared with strains of hospital-acquired methicillin-resistant *S aureus*, occurs in a younger population with a higher prevalence of injection drug use.\textsuperscript{80} *S aureus* IE is associated with higher rates of embolism and mortality compared with IE caused by other organisms.\textsuperscript{18,81,82} In a large cohort study of *S aureus* IE, embolism occurred in 60% of cases of *S aureus* IE versus 31% of cases caused by other organisms.\textsuperscript{18}

NVE caused by methicillin-susceptible strains of *S aureus* should be treated with 6 weeks of intravenous nafcillin or oxacillin (see Table 1). Gentamicin can be added for 3 to 5 days at 1 mg/kg every 8 hours, though its use is considered optional based on existing studies and potential toxicities.\textsuperscript{44–46} Methicillin-resistant *S aureus* IE should be treated with vancomycin alone for 6 weeks, with goal vancomycin troughs of 10 to 15 mg/dL.\textsuperscript{40} Antibiotic therapy for PVE caused by *S aureus* is shown in Table 2.

**Coagulase-Negative Staphylococci**

While coagulase-negative staphylococci cause about 6% of NVE, they cause very little acute IE.\textsuperscript{83} Coagulase-negative staphylococcal IE is more indolent than IE caused by other organisms. One significant exception is the species *Staphylococcus lugdunensis*, a coagulase-negative staphylococcus that behaves clinically like *S aureus*, and has been described to cause acute IE with an aggressive clinical course.\textsuperscript{84} In the first year after prosthetic valve implantation, coagulase-negative staphylococci are the second most common cause of PVE, after *S aureus*.\textsuperscript{71} IE caused by coagulase-negative staphylococci should be treated with antibiotic regimens similar to those used to treat *S aureus* (see Tables 1 and 2).

**Streptococci**

Streptococcal IE comprises about 30% of all IE, though it is less prevalent among acute IE.\textsuperscript{18} Most streptococcal IE is caused by viridans streptococci, which are oral flora and include *S mitis*, *S mutans*, *S salivarius*, *S sanguis*, and the *S intermedius* group (*S intermedius*, *S anginosus*, and *S constellatus*).\textsuperscript{11}

*Streptococcus bovis*, a group D streptococcal species, is the most common nonviridans streptococcal species to cause IE.\textsuperscript{85} *S bovis* bacteremia is strongly associated with colon polyps and cancer.\textsuperscript{86} *S bovis* accounts for 5% to 15% of cases of IE in the United States.\textsuperscript{85} Other streptococci account for less than 5% of cases of definite IE.\textsuperscript{18} Treatment of IE caused by viridans streptococci or by *S bovis* depends on the degree
<table>
<thead>
<tr>
<th>Organism</th>
<th>Drug</th>
<th>Duration</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxacillin-sensitive <em>Staphylococcus</em></td>
<td>Oxacillin/nafcillin 2 g IV q 4 h</td>
<td>6 wk</td>
<td>For nonanaphylactoid penicillin allergy, substitute cefazolin 2 g IV q 8 h for oxacillin/nafcillin; for anaphylactoid penicillin allergy, substitute vancomycin 15 mg/kg IV q 12 h for oxacillin/nafcillin, and do not use gentamicin</td>
</tr>
<tr>
<td></td>
<td>WITH OR WITHOUT Gentamicin 1 mg/kg IV/IM q 8 h&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3–5 d</td>
<td></td>
</tr>
<tr>
<td>Oxacillin-resistant <em>Staphylococcus</em></td>
<td>Vancomycin 15 mg/kg IV q 12 h&lt;sup&gt;b&lt;/sup&gt;</td>
<td>6 wk</td>
<td>—</td>
</tr>
<tr>
<td>Viridans streptococci/S bovis with penicillin MIC ≤ 0.12 μg/mL</td>
<td>Penicillin G 12–18 million U IV per 24 h&lt;sup&gt;c&lt;/sup&gt; OR Ceftriaxone 2 g IV/IM q24 h</td>
<td>4 wk</td>
<td>For penicillin/ceftriaxone allergy, vancomycin 15 mg/kg IV q 12 h&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Viridans streptococci/S bovis with penicillin MIC &gt; 0.12 to ≤ 0.5 μg/mL</td>
<td>Penicillin G 24 million U IV per 24 h&lt;sup&gt;c&lt;/sup&gt; PLUS Gentamicin 3 mg/kg IV/IM q 24 h OR Ceftriaxone 2 g IV/IM q 24 h PLUS Gentamicin 3 mg/kg IV/IM q 24 h</td>
<td>4 wk</td>
<td>For penicillin/ceftriaxone allergy, vancomycin 15 mg/kg IV q 12 h&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup> For nonanaphylactoid penicillin allergy, substitute cefazolin 2 g IV q 8 h for oxacillin/nafcillin; for anaphylactoid penicillin allergy, substitute vancomycin 15 mg/kg IV q 12 h for oxacillin/nafcillin, and do not use gentamicin.

<sup>b</sup> For nonanaphylactoid penicillin allergy, substitute cefazolin 2 g IV q 8 h for oxacillin/nafcillin; for anaphylactoid penicillin allergy, substitute vancomycin 15 mg/kg IV q 12 h for oxacillin/nafcillin, and do not use gentamicin.

<sup>c</sup> For nonanaphylactoid penicillin allergy, substitute cefazolin 2 g IV q 8 h for oxacillin/nafcillin; for anaphylactoid penicillin allergy, substitute vancomycin 15 mg/kg IV q 12 h for oxacillin/nafcillin, and do not use gentamicin.
<table>
<thead>
<tr>
<th>Viridans streptococci/ <em>S bovis</em> or nutritionally variant streptococci with penicillin MIC &gt; 0.5 µg/mL</th>
<th>See treatment regimen for penicillin/ampicillin-resistant enterococcal endocarditis</th>
<th>—</th>
<th>—</th>
</tr>
</thead>
</table>
| **Enterococcus** spp susceptible to penicillin, ampicillin, gentamicin, and vancomycin | Ampicillin 2 g IV q 4 h  
PLUS  
Gentamicin 1 mg/kg IV/IM q 8 h<sup>a</sup>  
OR  
Penicillin G 18–30 million U IV per 24 h<sup>c</sup>  
PLUS  
Gentamicin 1 mg/kg IV/IM q 8 h<sup>a</sup> | 4–6 wk | 4–6 wk  
PLUS 
gentamicin 1 mg/kg IV/IM q 8 h<sup>a</sup> for 6 wk |
| **Enterococcus** spp resistant to penicillin/ampicillin; susceptible to vancomycin and gentamicin | Vancomycin 15 mg/kg IV q 12 h<sup>b</sup>  
PLUS  
Gentamicin 1 mg/kg IV/IM q 8 h<sup>a</sup> | 6 wk | 6 wk  
PLUS gentamicin 1 mg/kg IV/IM q 8 h<sup>a</sup> for 6 wk |

All doses based on normal renal function.

*Abbreviations: IM, intramuscularly; IV, intravenously; MIC, minimum inhibitory concentration.*

<sup>a</sup> Target gentamicin peak 3–4 µg/mL; target trough <1 µg/mL.

<sup>b</sup> Target vancomycin peak 30–45 µg/mL; target trough 10–15 µg/mL.

<sup>c</sup> Penicillin dosing can be by continuous infusion, or dosed q 4–6 h in equal divided doses.

<table>
<thead>
<tr>
<th>Organism</th>
<th>Drug</th>
<th>Duration</th>
<th>Alternative/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxacillin-sensitive <em>Staphylococcus</em></td>
<td>Oxacillin/nafcillin 2 g IV q 4 h PLUS Rifampin 300 mg IV/PO q 8 h PLUS Gentamicin 1 mg/kg IV/IM q 8 h</td>
<td>≥ 6 wk</td>
<td>For nonanaphylactoid penicillin allergy, substitute cefazolin 2 g IV q 8 h for oxacillin/nafcillin; for anaphylactoid penicillin allergy, substitute vancomycin 15 mg/kg IV q 12 h for oxacillin/nafcillin</td>
</tr>
<tr>
<td>Oxacillin-resistant <em>Staphylococcus</em></td>
<td>Vancomycin 15 mg/kg IV q 12 h PLUS Rifampin 300 mg IV/po q 8 h PLUS Gentamicin 1 mg/kg IV/IM q 8 h</td>
<td>≥ 6 wk</td>
<td>—</td>
</tr>
<tr>
<td>Viridans streptococci/<em>S bovis</em> with penicillin MIC ≤ 0.12 μg/mL</td>
<td>Penicillin G 24 million U IV per 24 h OR Gentamicin 3 mg/kg IV/IM q 24 h OR Ceftriaxone 2 g IV/IM q 24 h</td>
<td>6 wk</td>
<td>For penicillin/ceftriaxone allergy, vancomycin 15 mg/kg q 12 h for 6 wk without gentamicin</td>
</tr>
</tbody>
</table>
### Viridans streptococci/S bovis with penicillin MIC > 0.12

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Description</th>
<th>Duration</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Penicillin G 24 million U IV per 24 h&lt;sup&gt;c&lt;/sup&gt; PLUS Gentamicin 3 mg/kg IV/IM q 24 h</td>
<td>6 wk</td>
<td>For penicillin/ceftriaxone allergy, vancomycin 15 mg/kg q 12 h&lt;sup&gt;b&lt;/sup&gt; for 6 wk without gentamicin OR Ceftriaxone 2 g IV/IM q 24 h PLUS Gentamicin 3 mg/kg IV/IM q 24 h</td>
<td>6 wk</td>
</tr>
</tbody>
</table>

### Enterococcus spp

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Description</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>PVE treatment regimens</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

---

All doses based on normal renal function.  

**Abbreviations:** IM, intramuscularly; IV, intravenously; MIC, minimum inhibitory concentration.  

<sup>a</sup> Target gentamicin peak 3–4 μg/mL; target trough <1 μg/mL.  

<sup>b</sup> Target vancomycin peak 30–45 μg/mL; target trough 10–15 μg/mL.  

<sup>c</sup> Penicillin dosing can be by continuous infusion, or dosed q 4–6 h in equal divided doses.  

of penicillin resistance of the infecting organism. Aminoglycosides are recommended in some settings for synergistic effects, though clinical data in humans is incomplete. See Tables 1 and 2 for treatment recommendations.

**Enterococci**

After staphylococci and streptococci, enterococci are the third leading cause of IE, causing about 10% of cases. Enterococcal IE tends to occur in older men with many comorbid medical conditions. It occurs disproportionally on the aortic valve, and is less commonly associated with embolic events compared with IE caused by other organisms. Enterococci were formerly designated as a member of genus *Streptococcus*, but now are a genus unto themselves. Unlike streptococci, enterococci are relatively resistant to penicillin, ampicillin, and vancomycin, and killing of susceptible strains often requires the addition of gentamicin or streptomycin for synergy. For this reason, all enterococcal isolates in IE cases should be tested for high-level resistance to gentamicin and streptomycin. Current guidelines suggest 4 to 6 weeks of aminoglycoside in combination with a cell wall–active agent for IE caused by appropriately susceptible isolates, but observational data suggest that outcomes may be similar when the aminoglycoside is given for a shorter duration. In cases where aminoglycoside is contraindicated because of toxicities, or when high-level resistance is present, there is in vitro data but limited clinical data suggesting that the combination of ampicillin and ceftriaxone achieve synergistic killing of susceptible enterococci, and may be a reasonable therapeutic alternative when aminoglycosides cannot be used. See Tables 1 and 2 for treatment recommendations.

**Gram-Negative Bacilli**

Gram-negative bacilli account for approximately 5% of IE diagnoses. These can be divided into HACEK and non-HACEK IE. The acronym HACEK stands for *Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, and Kingella*. IE due to HACEK organisms is rarely acute. Older literature suggest that these fastidious organisms require prolonged incubation periods to grow in the microbiology lab, but with modern culture techniques, most HACEK organisms grow within 5 days. In a recent international cohort including 2761 cases of IE from 2000 to 2005, only 1.8% of cases were caused by non-HACEK gram-negative organisms, most commonly *Escherichia coli* and *Pseudomonas aeruginosa*. Unlike older case series in which injection drug use was strongly implicated in the majority of cases, most cases in this cohort (57%) were health care–acquired, and mortality was high (24%).

**COMPLICATIONS**

**Congestive Heart Failure**

CHF is the most common complication of both NVE and PVE, occurring in over half of all cases of IE. It is usually caused by valvular dysfunction, not myocardial failure, and is most commonly associated with aortic valve dysfunction. In retrospective studies of IE patients with CHF, medical management alone is associated with higher mortality than surgical and medical management combined, even after adjustment for propensity to receive surgical therapy.

**Intracardiac Abscess**

Intracardiac abscesses occur in approximately 10% to 40% of cases of IE and are particularly common in PVE and aortic valve disease. Abscess related to the aortic valve can extend into the conduction system, causing heart block.
S aureus is the organism most commonly associated with intracardiac abscess.\textsuperscript{58,95,96} Diagnosis usually requires TEE, though even TEE has a sensitivity of only about 50% compared with intraoperative examination.\textsuperscript{97} Surgical intervention is usually necessary to achieve cure of abscess.\textsuperscript{54,95}

**Embolism**

Embolic events occur in 20% to 50% of patients with IE.\textsuperscript{98,99} The central nervous system is the most common destination of embolism, followed by the spleen, kidneys, lungs, and liver.\textsuperscript{55,98} Risk of embolism is highest in the time immediately following diagnosis, and risk decreases once antibiotic therapy has been initiated.\textsuperscript{100,101} Vegetations most likely to embolize are those measuring greater than 10 mm and those on the anterior mitral valve leaflet.\textsuperscript{55}

Central nervous system embolism accounts for 40% to 65% of all embolic events in IE, and the middle cerebral artery is the most common site.\textsuperscript{98,100} In a study of 60 patients with left-sided IE who underwent brain MRI, cerebrospinal fluid analyses, and structured neurologic examinations, 35% of patients had a symptomatic cerebrovascular event, and another 30% had an asymptomatic event, for a total incidence of 65%.\textsuperscript{102} The risk of central nervous system embolism declines after initiation of antimicrobial therapy.\textsuperscript{102,103} In a prospective study of 1437 patients with left-sided IE at 61 medical centers, the risk of central nervous system embolism declined by 65% between the first and second week of antibiotics.\textsuperscript{104}

**Mortality**

Mortality among IE patients has been estimated at 15% to 20% during the index hospitalization, and 20% to 30% at 1 year.\textsuperscript{20,99,104–106} Mortality is similar between NVE and PVE, and between mitral and aortic IE.\textsuperscript{55} Right-sided IE has lower mortality than left-sided disease.\textsuperscript{55} In NVE, viridans streptococci and enterococci are associated with lower mortality compared with S aureus.\textsuperscript{20} IE caused by gram-negative bacilli and fungi has greater than 50% mortality.\textsuperscript{55} Nosocomial acquisition of IE,\textsuperscript{107} older age,\textsuperscript{99} immunocompromise,\textsuperscript{29} diabetes mellitus,\textsuperscript{104} Acute Physiology and Chronic Health Evaluation Score II (APACHE II) score,\textsuperscript{104} hemodynamic instability,\textsuperscript{29} altered mental status,\textsuperscript{29,106,107} and renal failure\textsuperscript{99,106,107} are significant predictors of mortality. IE complications predictive of mortality include CHF,\textsuperscript{18,99} intracardiac abscess,\textsuperscript{18} embolism,\textsuperscript{29,106,107} and large mobile vegetation.\textsuperscript{27,99,106}

**PREVENTION**

Though there have been no randomized controlled trials that prove the effectiveness of IE prophylaxis around the time of dental, gastrointestinal, or genitourinary (GU) procedures, it has been common practice since the 1950s.\textsuperscript{4} Recent literature, however, has shown that only a small percentage of IE cases are attributable to dental procedures, and that a huge amount of prophylaxis would be needed to prevent only a small number of cases.\textsuperscript{4,108,109}

The most recent practice guideline from the American Heart Association for the Prevention of Infective Endocarditis, published in 2007, calls into question many of the long-held assumptions about IE prevention, and contains many new and revised recommendations.\textsuperscript{4} Prophylaxis solely for IE prevention is recommended only in patients undergoing a high-risk procedure, and with a high-risk cardiac lesion. A high-risk procedure is defined as (1) any dental procedure that involves manipulation of gum tissue, or the periapical region of teeth, or perforation of oral mucosa; (2) invasive respiratory tract procedure involving breaks in the respiratory mucosa; or (3)
invasive procedure involving infected skin or soft tissue. A high-risk cardiac lesion is defined as one of the following: (1) prosthetic heart valve or prosthetic material used in a valve repair; (2) previous IE; (3) unrepaired cyanotic heart disease; (4) completely repaired congenital heart defect in the first 6 months after repair only; (5) repaired congenital heart defect with residual defect adjacent to prosthetic material; or (6) cardiac transplant recipient with cardiac valvulopathy. Prophylaxis is no longer recommended for those undergoing gastrointestinal or GU procedures.4

SUMMARY

Acute IE is a complex disease with changing epidemiology and a rapidly evolving knowledge base. To consistently achieve optimal outcomes in the management of IE, the clinical team must have an understanding of the epidemiology, microbiology, and natural history of IE, as well as a grasp of the guiding principles of diagnosis and medical and surgical management.

REFERENCES


